Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Janssen
Janssen
J&J claims first approval for PARP combo Akeega
Pharmaphorum
Mon, 04/24/23 - 10:22 am
JNJ
Janssen
Akeega
PARP inhibitors
metastatic castration-resistant prostate cancer
Europe
J&J records $130M restructuring expense in Q1 overhaul of infectious disease unit
Fierce Biotech
Tue, 04/18/23 - 10:13 am
JNJ
Janssen
earnings
restructuring
infectious disease
Citing J&J's 'failure to comply' with court rules, judge nixes early bid to block Amgen's Stelara biosim
Fierce Pharma
Fri, 03/3/23 - 11:56 am
JNJ
patents
Janssen
Amgen
biosimilars
Stelara
After spending $6.5B for Momenta, J&J readies 'pipeline in a product' for pivotal year
Fierce Biotech
Mon, 02/27/23 - 10:09 am
JNJ
Janssen
nipocalimab
Momenta Pharmaceuticals
Janssen Returns Phase I NASH Candidate to Arrowhead
BioSpace
Wed, 02/15/23 - 06:08 pm
JNJ
Janssen
RNAi
Arrowhead Pharmaceuticals
NASH
Roche expands collaboration with Janssen to advance personalised healthcare through companion diagnostics
BioSpace
Thu, 02/9/23 - 10:53 am
Roche
Janssen
JNJ
companion diagnostics
diagnostics
J&J clears PhII for rare blood disorder with drug from $6.5B Momenta buyout
Endpoints
Mon, 02/6/23 - 10:41 am
JNJ
Momenta
Janssen
nipocalimab
clinical trials
Janssen laying off 4 dozen employees as California plant heads toward closure
Fierce Pharma
Thu, 02/2/23 - 10:59 pm
JNJ
Janssen
layoffs
California
drug manufacturing
Doxil
Concerta
Morphic Loses Another Big Pharma as J&J Bails on Research Deal
BioSpace
Mon, 01/23/23 - 11:13 am
JNJ
Janssen
Morphic Therapeutic
R&D
ADC deals: Mersana engages with Merck, LegoChem and Amgen collaborate
Biopharma Reporter
Mon, 01/2/23 - 06:41 pm
antibody-drug conjugate
Merck
LegoChem Biosciences
Mersana
Amgen
GSK
Janssen
Setting the Stage for ASH 2022
BioSpace
Fri, 12/9/22 - 10:50 am
ASH 2022
AstraZeneca
Janssen
Merck
Vega Therapeutics
Janssen Bows Out as Contender for Horizon Therapeutics Buyout
BioSpace
Mon, 12/5/22 - 10:59 am
Horizon Therapeutics
M&A
Agmen
Sanofi
Janssen
JNJ
J&J sues Amgen over plan to sell drug similar to Stelara
Business Insurance
Thu, 12/1/22 - 10:48 am
JNJ
Janssen
Amgen
legal
ulcerative colitis
patents
Stelara
J&J unit, happy with AC Immune Alzheimer's work, moves 1 of 2 shots to next step
Fierce Biotech
Thu, 12/1/22 - 10:33 am
JNJ
AC Immune
Alzheimer's disease
Janssen
vaccines
ACI-35.030
Janssen’s Phase IIIb major depressive disorder trial meets primary endpoint
Clinical Trials Arena
Sat, 11/26/22 - 07:17 pm
Janssen
JNJ
clinical trials
Spravato
treatment-resistant depression
Janssen Steps Away from Phase I Prostate Cancer Study, Cites Patient Enrollment Issues
BioSpace
Mon, 10/31/22 - 04:14 pm
Essa Pharma
Janssen
JNJ
prostate cancer
clinical trials
EPI-7386
New TREMFYA Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis
Marketscreener
Tue, 10/25/22 - 10:53 am
JNJ
Janssen
clinical trials
ulcerative colitis
Tremfya
Janssen Touts Positive Mid-Late Stage Data From Two Ulcerative Colitis Trials
BioSpace
Mon, 10/10/22 - 10:52 am
JNJ
Janssen
ulcerative colitis
guselkumab
golimumab
Janssen reports Phase II data for Darzalex-RVd to treat multiple myeloma
Clinical Trials Arena
Mon, 08/29/22 - 10:32 am
JNJ
Janssen
clinical trials
Darzalex
Revlimid
Velcade
Multiple Myeloma
Janssen secures FDA breakthrough designation for myeloma therapy
Pharmaceutical Business Review
Thu, 06/30/22 - 10:54 am
JNJ
Janssen
breakthrough therapy
FDA
talquetamab
Multiple Myeloma
relapsed or refractory multiple myeloma
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »